Dexcom Inc - DXCM STOCK NEWS

Dexcom, a leader in continuous glucose monitoring (CGM) technology, announced that its Dexcom ONE sensor will now be reimbursed for around 100,000 Type 2 diabetes (T2D) patients in France. This decision allows individuals over 2 years old, on non-intensified insulin therapy, and with HbA1c ≥ 8% to access this technology. France becomes the first European country to offer full national reimbursement for CGM for T2D patients. This follows similar moves in the USA and New Zealand. Further, Germany's KKH health insurance provider has also started reimbursing Dexcom sensors for T2D patients. Dexcom's survey in the UK revealed that 63% of T2D patients face challenges in managing their condition, and 83% are open to using CGM technology. With T2D diagnoses rising globally, the adoption of CGM technology like Dexcom's could improve management and reduce healthcare costs.

Dexcom announced that Nova Scotia now provides coverage for Dexcom G6 and G7 continuous glucose monitoring (CGM) systems for residents with type 1 or type 2 diabetes who use intensive insulin and meet eligibility criteria.

This is part of the province's Pharmacare programs and a new income-based Sensor-Based Glucose Monitoring Program, aimed at reducing out-of-pocket costs for diabetes management tools.

Nova Scotia joins other provinces like New Brunswick, Newfoundland and Labrador, British Columbia, Manitoba, and Prince Edward Island in offering such coverage.

Dexcom's CGM systems, including the newly introduced G7, are clinically proven to reduce A1C, improve time in range, and reduce hypoglycemic events.

Dexcom (NASDAQ: DXCM) announced that its Executive Vice President and Chief Financial Officer, Jereme Sylvain, will present an update at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th.

The presentation will start at 4:20 PM EST and will be available via live webcast. The webcast can be accessed through the Dexcom Investor Relations website and will be archived for future reference.

Tandem Diabetes Care announced the compatibility of its Tandem Mobi insulin pump with both Dexcom G7 and G6 CGM systems.

This integration enhances user flexibility, allowing choice in diabetes management. Tandem Mobi, the smallest automated insulin delivery system, launched in the U.S. earlier in 2023, offers greater discretion and comfort.

Users will receive free software updates for this feature via email. New pumps will ship with the updated software pre-loaded.

This move strengthens Tandem's partnership with Dexcom and builds on their decade-long collaboration in providing innovative diabetes solutions.

Dexcom has launched the Dexcom ONE+ sensor in the UK, incorporating 25 years of research to assist individuals with Type 2 diabetes in monitoring their glucose levels in real-time. The first-ever 'Dexcom State of Type 2 Report' reveals that a significant number of people with Type 2 diabetes experience anxiety and depression, and many struggle to manage their condition effectively. The report highlights that 54% of respondents wish they had more confidence in managing their diabetes, and 63% face challenges in improving their diet or mental health. Additionally, 48% of participants believe glucose monitoring could improve their condition management.

Dexcom ONE+ aims to provide a tailored solution for people with Type 2 diabetes, enhancing user motivation and diabetes management by providing real-time feedback. The report is intended to serve as a resource for healthcare professionals and empower those with Type 2 diabetes to feel less isolated.

Dexcom, Inc. (Nasdaq: DXCM) reported strong financial results for the first quarter of 2024, with revenue growing 24% year-over-year to $921.0 million. The company's U.S. and international revenue also saw significant growth. Dexcom received FDA clearance for its new CGM system, launched new products in European countries, and published its annual Sustainability Report. The company's operating income and net income showed substantial increases, reflecting a positive outlook for the future.

DexCom, Inc. releases its annual Sustainability Report, showcasing advancements in corporate sustainability disclosures, including expanded greenhouse gas emissions data and increased transparency in pay-equity practices. The report highlights key initiatives aligned with Dexcom's core values and business strategy, emphasizing its commitment to stakeholders and global health through access to CGM technology.

DexCom, Inc. (DXCM) plans to release its first quarter 2024 financial results on April 25, 2024. A conference call will be held to review the performance, starting at 4:30 p.m. (Eastern Time) on the same day.

DexCom, Inc. (NASDAQ:DXCM) announces FDA clearance for Stelo, the first glucose biosensor in the US that doesn't require a prescription. Stelo, a small wearable sensor worn on the back of the upper arm, will provide glucose insights directly to a user's smartphone. Created by the makers of Dexcom G7, Stelo aims to empower people with Type 2 diabetes not using insulin to take control of their health. Available summer 2024, Stelo will cater to the approximately 25 million people in the US living with Type 2 diabetes who do not use insulin and can benefit from continuous glucose monitoring technology.